High-frequency ultrasound helps doctors see beneath surface of EB skin
Painless scans offer way to monitor fragile skin without invasive biopsies
Written by |
A noninvasive ultrasound technique successfully “saw” through the skin of a teenager with severe recessive dystrophic epidermolysis bullosa (RDEB), detecting hidden inflammation and scarring without causing the patient any pain.
According to a new case report, high-frequency ultrasound (HFUS) allowed doctors to map disease activity beneath the skin surface of a 16-year-old boy. The technology provided detailed, objective measurements of swelling and fluid buildup that are often invisible to the naked eye or require painful, invasive biopsies to identify.
Researchers suggest this painless imaging could change how doctors monitor epidermolysis bullosa (EB) progression and measure the success of new treatments, such as recently approved gene therapies.
“These are particularly interesting prospects given recent advancements in EB treatments,” they wrote, noting that the technique offers a much-needed objective tool for clinical practice.
The study, “Non-invasive Analysis of Skin in Recessive Dystrophic Epidermolysis Bullosa Using High-Frequency Ultrasound: A First Case Report,” was published in the journal Acta Dermato-Venereologica.
Challenges of monitoring fragile skin
Epidermolysis bullosa is a group of rare disorders that affect the skin and mucous membranes, leading to symptoms such as fragile skin, blisters, and poorly healing wounds. After diagnosis, people with EB require lifelong follow-up, particularly those with severe forms of the disease.
However, conventional methods for monitoring disease progression often rely on invasive techniques that cannot be repeated. Visual inspection, another strategy, can be subjective and may miss subtle changes occurring in the inner skin layers.
HFUS offers a potential alternative. This noninvasive imaging technique enables clinicians to examine skin layers and provide detailed measurements of skin thickness, inflammation, and structural changes. In particular, the subepidermal low-echogenic band (SLEB), found beneath the outer skin layer, has been linked to skin inflammation in other diseases, with thicker bands reflecting greater swelling and immune cell infiltration.
In this case report, researchers in Sweden explored whether HFUS could detect and quantify skin changes associated with RDEB.
The teenage patient had widespread, recurrent wounds affecting much of his body, including difficult-to-heal areas, such as the knees and armpits. He also experienced chronic pain, itching, and digestive complications that required tube feeding. He had not received gene therapy.
The team scanned an area of the boy’s abdomen that showed blistering and scarring, bordered by normal-appearing skin. Multiple ultrasound scans were taken across this transition zone to assess how skin structure changed from healthy-looking tissue to inflamed and blistered areas.
The images revealed clear and progressive differences beneath the skin surface. In areas that appeared clinically normal, the dermal layer was uniform and resembled that of healthy individuals. As the scans moved toward inflamed skin, a distinct SLEB began to appear and became increasingly prominent. The thickest and darkest SLEB signals were observed in areas with redness and early blistering.
Quantitative analysis showed marked differences between regions, with regions becoming thicker in areas of redness, particularly where blistering was present. Similarly, the proportion of low-density ultrasound signals, reflecting inflammation and fluid buildup, increased steadily from normal skin to red, blistered skin. In contrast, the thickness of the outer skin layer did not differ noticeably between regions, suggesting that HFUS detected inflammatory changes deeper in the skin.
Monitoring the impact of new gene therapies
Importantly, the ultrasound examination caused no pain or discomfort, according to the patient.
Overall, this case report supports the use of noninvasive HFUS to detect and measure inflammation-related skin changes in EB. The procedure could become a valuable tool for monitoring disease severity and treatment response over time.
“These are particularly interesting prospects given recent advancements in EB treatments, especially the approvals of the topical gene therapies [Vyjuvek — beremagene geperpavec] and prademagenezamikeracel (Zevaskyn),” the team wrote.
However, “validation in larger and more diverse patient cohorts is needed to establish its clinical utility,” the researchers concluded.
